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Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon and rectum, which is positively
correlated with the occurrence of IBD-related colorectal cancer (IBD-CRC). Conventional therapies based on drugs
such as corticosteroids, mesalamine, and immunosuppression have serious side effects. Pulsatillae decoction (PD)
served as a classical prescription for the treatment of colitis in China, has been shown to exert prominent curative
effects and good safety. Based on clinical experience and our amelioration, we added an extra herb into this
classical prescription, but its therapeutic effect on UC and the underlying mechanism are still unclear.
Results: We first found the curative effect of modified PD on dextran sodium sulfate (DSS)-incubated NCM460 cells.
Then C57BL/6 mice were administered DSS to induce UC to evaluate the therapeutic of modified PD. The results
showed that modified PD alleviated the inflammatory injury, manifested in body weight, colon length, and disease
activity index, with histological analysis of colon injury. Transcriptomic sequencing indicated that modified PD
treatment downregulated the IL-6/STAT3 signaling pathway, and reduced the levels of p-NF-κB, IL-1β and NLRP3,
which were confirmed by western blot.
Conclusions: Collectively, our results indict that modified PD could efficiently relieve clinical signs and
inflammatory mediators of UC, providing evidence of the anti-colitis effect of modified PD, which might provide
novel strategies for therapeutic intervention in UC, which may be applied to the prevention of IBD-CRC.
Keywords: Modified Pulsatillae decoction, NCM460, DSS, Ulcerative colitis, IL-6/STAT3 pathway
Background
Inflammatory bowel disease (IBD), including ulcerative col-
itis (UC) and Crohn’s disease (CD), is a chronic and recur-
rent inflammatory disorder of unknown etiology [1]. Its
duration and severity are positively correlated with the oc-
currence of IBD-related colorectal cancer (IBD-CRC) [2]. A
recent comparative study in China and Canada showed that
compared with CD, the proportion of UC in China was
significantly higher among patients with IBD-CRC [3]. The
global burden of UC is rising, including the associated
healthcare and societal costs. According to US data, the na-
tional annual direct and indirect costs related to UC are es-
timated to be $8.1 billion–$14.9 billion with a prevalence of
238/10000 [4, 5]. Although studies of the Chinese popula-
tion have shown that the incidence of UC has recently in-
creased, with the economic development and improvement
of living standards, the incidence is 1.09–1.64 / 100,000 [2,
3]. Hitherto the precise cause of UC is unknown, recent
research indicates that the individual’s genetic sensibility,
external environment and commensal microflora are all
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involved and functionally integrated in the pathogenesis of
UC [4, 5]. It is reported that patients with UC express high
levels of immunocytokines such as TNF-α and IL-6 [6].
The goal of clinical treatment is to achieve disease re-
mission, prevent disease-related complications, and im-
prove the quality of patients’ life. In the past decades, the
conventional therapies for UC have been based on the use
of corticosteroids, mesalamine and immunosuppressive
drugs. Unfortunately, nearly one-third of the patients who
are prescribed steroids requires repeated dosing or persists
with refractory disease [7]. Currently biological therapies
especially tumor necrosis factor (TNF) inhibitors such as
infliximab (IFX), adalimumab (ADA), certulizumab pegol
and golimumab start to matter. However, anti-TNF ther-
apy has been accompanied with a certain number of side
effects including the risk of serious infections and the oc-
currence of fatal T cell lymphoma on account of rapid de-
crease of the T-cell population in the gut tissue [8].
Therefore, there is an urgent need to develop safe and ef-
fective therapies for treating UC.
Herbal medicine, the most common modality of com-
plementary treatment, exhibits the abilities of bacteriosta-
sis, anti-inflammation, and anticancer, which has already
been used for treating some diseases since the third cen-
tury B.C. in China. It has emerged as the alternative treat-
ment for inflammatory diseases of late years, including
UC. Several studies have shown that herbal medicine and
its extracts exert anti-UC effects in vitro and in vivo [9–
11]. Pulsatilla decoction (PD) was first prescribed by an-
cient Chinese physicians Zhang Zhongjing in his medical
book “Shang Han Lun”, approximately 1800 years ago.
Studies have indicated that PD has multiple therapeutic
functions including the anti-C. albicans, anti-diarrhea and
anti-inflammatory activity [12–14]. However, our previ-
ously experiment showed that therapeutic effect of PD on
UC was unsatisfactory. The Traditional Chinese Medicine
pathogenesis of UC is “combination of excess and defi-
ciency”, its therapeutic medication should be a combin-
ation of “dispelling pathogenic factors and strengthening
vital energy”. The effect of the initial formulation of
Pulsatillae decoction is clearing away heat, detoxify
and cooling blood. Based on clinical experience and
our amelioration, we added an extra herb, Rhizoma
Atractylodis Macrocephalae, to strengthen vital en-
ergy, but its therapeutic effect on UC and the under-
lying mechanism are still unknown.
In this study, Dextran sulfate sodium (DSS)-induced
colitis mice model, which is characterized by the mor-
phologically and biochemically, was utilized to investi-
gate the therapeutic effect of modified PD, providing
evidence of the utilization of modified PD for treating
UC [10]. Furthermore, the study on mechanism also elu-
cidated that IL-6/STAT3 signaling pathway was involved
in the action of modified PD for alleviating UC.
Results
Modified PD alleviated DSS-induced injury in NCM460
cells
To explore the effect of modified PD on DSS-induced
UC, we first utilized the NCM460 cell line to evaluate
the effect of DSS on cell viability. Cells were treated with
a series of concentrations of DSS for 24 h and 48 h, and
the cell viability was determined by MTT assay. As
shown in Fig. 1A, we found that DSS significantly de-
creased cell viability and exerted its most deleterious ef-
fect at a minimum concentration of 0.2 μg/mL.
Meanwhile, to assess the therapeutic effect of modified
PD against the cell damage induced by DSS, we per-
formed the exposure of NCM460 cells to modified PD
and DSS simultaneously. Results showed that modified
PD treatment ameliorated cell viability, and exerted the
most effective action at 100 μg/mL (Fig. 1B). These data
indicated that modified PD alleviated DSS-induced in-
jury in NCM460 cells.
Modified PD relieved DSS-induced UC in vivo
To further determine the protective role of modified PD
against DSS-induced UC, we then explored whether
modified PD could exert similar effect in vivo. Modified
PD was given to an animal model of UC induced by DSS.
As presented above, C57BL/6 mice were given 2.5% DSS
(w/v) in their drinking water for the induction of acute
UC and were simultaneously administered modified PD at
a concentration of 3.185, 6.37 and 12.74 g/kg for 10 days
(Fig. 2A). Body weight was recorded every day and the an-
imals were sacrificed at 11th day, after which their colons
were stored in formalin. As shown in Fig. 2B, the greatest
weight loss was observed in the group treated with DSS
alone, while the body weight in control group was almost
unchanged. Mice given modified PD experienced less
weight loss than those given DSS alone, which was closely
related to the drug dose. The colon length and patho-
logical grading also demonstrated the above conclusion
(Fig. 2C-E). Additionally, H&E staining of the colon sec-
tions indicated that modified PD significantly abolished
the immunological injury in DSS-treated colon tissues
(Fig. 2F). Taken together, these results showed that modi-
fied PD ameliorated DSS-induced UC in vivo.
Transcriptome sequencing (RNA-seq) analysis hinted the
potential signaling pathway involved in DSS-induced UC
with modified PD treatment
To determine the underlying mechanism of modified PD
mitigating DSS-induced UC, transcriptome sequencing
(RNA-seq) analysis was performed to detect differential
expression profiles in the colon of NC, DSS and modified
PD groups. MA plots and volcano plots of the fold change
in gene expression for comparison between each two
groups are shown in Fig. 3A, in which we found 2573
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differential genes between normal and DSS group, 2019
differential genes between DSS and modified PD group,
1062 differential genes between normal and modified PD
group |foldchange| ≥2 and p value ≤0.05 were deemed sig-
nificantly. Figure 3B displayed a more concrete compari-
son by showing heatmaps and cluster analysis between
each two groups. These preliminary analyses reveal that
modified PD indeed elicits therapeutic effects on DSS-
induces UC.
To identify the transcriptomic pathways affected by the
DSS and modified PD, the gene ontology (GO) analysis
and Kyoto encyclopedia of genes and genomes (KEGG)
analysis were utilized (Fig. 3C). As shown Fig. 3D, DSS
treatment led to activation of Jak/STAT signaling path-
way, whereas modified PD reversed this tendency. Add-
itionally, we noticed that level of IL-6 varied with the DSS
and modified PD treatment. Thereby these genes and
pathways might play important roles in the DSS-induced
UC and in therapeutic effect of modified PD.
Modified PD inhibits DSS-induced activation of IL-6/STAT3
signaling pathway in vitro and in vivo
Previous study has shown that inhibiting or blocking the
activation of IL-6/STAT3 signaling pathway can attenu-
ate the colon injury and inflammation in DSS-induced
colitis, and RNA-seq analysis also pointed out that the
underlying mechanism may related with IL-6/STAT3
pathway. To confirm this, we first selected the NCM460
cell to validate it. As shown in Fig. 4A&B, western blot
showed that DSS treatment significantly increased the ex-
pression of NLRP3, IL-1β, IL-6 and TNF-α, meanwhile
the phosphorylation levels of several marker proteins of
IL-6/STAT3 signaling pathway (STAT3 and NF-κB) were
also manifested a remarkable upward trend compared to
matched controls. However, modified PD could restore
this increment. In addition, modified PD treatment signifi-
cantly inhibited the elevated mRNA expressions of VEGF,
IL-6 and TNF-α in colonic tissues of DSS-treated mice,
which illustrated that the adverse effects of modified PD
might be mediated by the IL-6/STAT3 pathway (Fig. 5A).
Moreover, the results of protein levels in colonic tissues
were consistent with NCM460 cell (Fig. 5B&C). Taken to-
gether, modified PD could downregulate DSS-activated
IL-6/STAT3 signaling pathways and suppress inflamma-
tory cytokines production. These findings indicated that
IL-6/STAT3 played an important role in DSS-induced
acute UC, and modified PD could alleviate oxidative injury
in the DSS-induced mouse model of UC.
Discussion
DSS, a low-molecular weight sulfated polysaccharide,
was utilized in inducing epithelial damage and inflam-
matory response in the colon in experimental mouse
model, which could provide signs of acute colitis includ-
ing weight loss, bloody stools, and diarrhea [15]. Besides,
given the massive application of murine colitis model on
acute colitis study, we chose C57BL/6 mice to perform
the experiments [16–19]. As previously mentioned, the
cause and underlying mechanisms of UC remain un-
clear, but what can be determined is that the chronic
relapsing-remitting inflammatory condition recruits pro-
inflammatory cytokines such as interleukin-6 (IL-6), IL-
1β, TNF-α and interferon-γ (IFN-γ), thereby resulting in
Fig. 1 Modified PD ameliorated DSS-induced cell injury on cell viability(A) NCM460 cells were incubated with various concentrations of DSS for
24 and 48 h and their viability were determined by MTT assay. (B) Cell viability of NCM460 treated with different dosages of modified PD and DSS
was analyzed by MTT assay. *: p < 0.05; ***: p < 0.001. Data are expressed as mean ± SEM.
Table 1 Formulation of modified PD
ingredient full taxonomic name
1 Pulsatillae Radix Pulsatilla chinensis (Bge.) Regei
2 Fraxini Cortex Fraxinus rhynchophylla Hance
3 Phellodendri Chinensis Cortex Phellodendron chinense Schneid.
4 Coptidis Rhizoma Coptis chinensis Franch.
5 Atractylodis Macrocephalae Rhizoma Atractylodes macrocephala Koidz.
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severe colon injury [20]. The conventional treatments
for UC including aminosalicylates, corticosteroids, and
immune modulators, such as sulfasalazine and glucocor-
ticosteroids, induce remission in only half of patients
[21]. However, these chemotherapies can cause serious
side effects like vomiting, anemia and generalized edema
which can be life-threatening [10]. Due to its obscure
etiology, high risk of recurrence, and poor prognosis,
UC has become a clinical challenge in terms of treat-
ment. Therefore, studies on the alternative therapies for
inflammatory chronic disease, especially UC, have been
the sudden explosion of great interest recently.
Traditional Chinese Medicine (TCM) is one of the
most developed branches of herbal medicine, which use
plants or/and plant extracts for medical treatment. It has
been recorded that a number of natural products exhibit
effectiveness for the treatment of UC, including Curcu-
min, Cannabinoids, Andrographis paniculate, Triptery-
gium wilfordii, et al. [22–24]. Pulsatilla decoction, which
consists of namely Radix Pulsatillae, Rhizoma Coptidis,
Cortex Phellodendri and Cortex Fraxini, is a TCM for-
mulation derived from a medical book “Shang Han Lun”
written by an ancient Chinese physicians Zhang Zhongj-
ing about 1800 years ago. Several trials have shown that
the prescription exerted prominent anti-inflammatory
effect, especially on enteritis and bacillary dysentery [25].
Based on the classical prescription and our clinical ex-
perience, we improved the proportion of ingredients in
Pulsatilla decoction, and added another herbal plant,
roasted Rhizoma Atractylodis Macrocephalae.
In our study, we examined whether modified PD alle-
viated the severity in tissue affected by colitis, the results
showed that treatment with modified PD improved the
extent of damage in colon suffering UC. Besides, tran-
scriptome sequencing indicated that IL-6/STAT3 signal-
ing pathway may be involved in the anti-inflammatory
mechanism of modified PD. Western blot verified the
decreased expression of IL-6 and p-STAT3 in colon tis-
sue. Meanwhile, the expression of NF-κB, NLRP3, IL-1β
and TNF-α were diminished. Through IL-6/STAT3 sig-
naling pathway, modified PD could inhibit the increased
inflammatory response and reduce the severity of colitis
lesions (Fig. 6). The multi-target effect of TCM formula-
tion lead us to wonder whether modified PD functions
by influencing other signaling pathway. KEGG pathway
classification from transcriptome sequencing reveal that
TLR4/MyD88 signaling is one of the most significantly
enriched pathways, which play a vital role mediating in-
flammation response. TLR4 mainly recognizes pathogen-
associated molecules and after being stimulated, TLR4 re-
cruits and activates downstream IRAK, ARAK2 and
TRAF6, eventually regulating MAPK, IRF5, NF-κB and as a
result, terminal inflammatory factors IL-1β and TNF-α are
released [26]. Several researches have showed that various
TCM formulations and compounds could alleviate inflam-
matory bowel diseases through TLR4/MyD88 pathway
[27–29], nonetheless whether modified PD takes effect
through via this signaling still needs further investigation.
Our work indicated the anti-colitis potential of modified
PD in vitro and in vivo, shedding light on UC interruption
through utilizing modified PD. Further animal experi-
ments show that modified PD can significantly improve
the symptoms of stool with pus and blood and weight loss
in the acute stage of inflammation, and significantly re-
duce the occurrence of IBD-CRC when used to treat
AOM/DSS-induced IBD-CRC. The mechanism remains
to be further elucidated.
Conclusions
In summary, we demonstrated that modified PD could
inhibit the increased inflammatory response and reduce
the severity of colitis lesions through IL-6/STAT3 signal-
ing pathway. Meanwhile, modified PD decreased the ex-
pression of NF-κB, NLRP3, IL-1β and TNF-α. These
results suggest that the anti-colitis potential of modified
PD in vitro and in vivo, shedding light on UC interrup-
tion through utilizing modified PD.
Methods
Cell culture
NCM460 cells were purchased from Xunian Biological
Technology Co., Ltd. (Shanghai, China). Cells were
maintained in Dulbecco’s Modified Eagle Medium
(Gibco, Grand Island, NY) with 10% fetal bovine serum
(FBS) (Gibco, Grand Island, NY), and penicillin and
streptomycin (P/S) solution (Sigma, St. Louis, MO) in a
37 °C incubator with humidified atmosphere of 5% CO2.
Reagents
Chinese herbal medicine was purchased from Nanjing Hos-
pital of TCM affiliated to Nanjing University of Chinese
Medicine, decoctioned to the appropriate concentration in
Table 2 Primers used in Quantitative real-time PCR (qRT-PCR)
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Fig. 2 Modified PD administration alleviated symptoms of DSS-induced UC(A) Mice were divided into negative control group, model group (DSS-
treated) and three modified PD groups (DSS-treated with modified PD treatment): low dose (3.185 mg/kg), medium dose (6.37 mg/kg) and high
dose (12.74 mg/kg). (B) Loss of basal body weight, (C & D) colon length, (E) Pathological score, and (F) HE staining was performed to evaluate the
therapeutic effect of modified PD. *: p < 0.05, **: p < 0.01, ***: p < 0.001, Data are expressed as mean ± SEM.
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Fig. 3 High-throughput transcriptomic sequencing of negative control group, model group and modified PD group (n = 3 in every group)(A) The
MA plot and volcano plot were used for showing variance in gene expression with respect to fold change (FC) and significance (p-value). Each
dot represents an individual gene: The red point in the plot represented significantly upregulated or downregulated RNA (fold change> 2, P <
0.05) and the black point demonstrated RNA with no statistical differences (fold change< 2, P > 0.05) (Left: negative control group vs. model
group; Middle: model group vs. modified PD group; Right: negative control group vs. modified PD group). (B) Microarray heat map demonstrates
clustering of colon tissues (Left: negative control group vs. model group; Middle: model group vs. modified PD group; Right: negative control
group vs. modified PD group). (C) GO classification of target genes. The 30 most significantly enriched GO terms for colon tissues between model
group and modified PD group. (D) KEGG pathway classification of target genes. The Y-axis showed the name of pathway and the X-axis
represented the rich factor. The point size indicated the number of differentially expressed genes in one pathway, and the color of the point
corresponded to the range of the Q value. The 20 most significant up-regulated pathways (model group vs. modified PD group).
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Fig. 4 Marker proteins expression of IL-6/STAT3 pathway(A) Western blot analysis of NLRP3, STAT3, p-STAT3, NF-κB, p-NF-κB, p-p65, IL-1β, IL-6 and
TNF-α of expression in NCM460 cell. (B) The quantitative analysis for western blot. *: p < 0.05, **: p < 0.01, ***: p < 0.001. Data are expressed
as mean ± SEM.
Fig. 5 Modified PD mitigated inflammation in DSS-induced UC in vivo. Colon tissues of negative control group, model group (DSS-treated) and
modified PD group (DSS-treated with modified PD treatment) were collected. (A) qRT-PCR results indicating modified PD treatment reduced
mRNA level of IL-6, VEGF and TNF-α (Modified PD represent high dose modified PD treatment mice herein). (B) Effect of modified PD on the
protein expression of NLRP3, STAT3, p-STAT3, NF-κB, p-NF-κB, p-p65, IL-1β, IL-6 and TNF-α. Protein expression levels were analyzed by Western
Blot. (C) The quantitative analysis for western blot. *: p < 0.05, **: p < 0.01, ***: p < 0.001. Data are expressed as mean ± SEM.
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the laboratory, stored at 4 °C after dispensing, then used for
gavage. Common names and Latin names of ingredients in
modified PD are presented in Table 1. TNF-a (#11948), IL-
1β (#12703), IL-6 (#12153), STAT3 (#4904), phospho-
STAT3 (#9145), NF-κB (#8242), phospho-NF-κB (Ser468)
(#3039), NLRP3 (#15101) and β-actin (#4970) were pur-
chased from Cell Signaling Technology (Danvers, MA).
Dextran sulphate sodium (DSS; 36–50 kDa) was obtained
from MP Biomedicals (Illkirch, France).
Cell viability assay
The cells were seeded into 96-well plates and treated
with drug at a serious of concentrations for 24 h and 48
h. After treatments, cells were incubated with MTT
(Solarbio, Shanghai, China) for 4 h at 37 °C. Then the
supernatant was removed, and the formazan crystals
were dissolved in 200 μL dimethyl sulfoxide. Finally, the
optical density was measured at 570 nm with a micro-
plate plate reader (Thermo Fisher Scientific, Inc., USA).
Mouse model
Eight-weeks-old female C57BL/6 mice were purchased
from Nanjing Qinglongshan Animal Breeding Base
(Nanjing, China). All animals were reared in an SPF-
level laboratory (temperature 24–25 °C, humidity 70–
75%, with a 12 h light/dark lighting regimen) and were
fed a standard diet of pellets and water ad libitum. Ani-
mal welfare and experimental procedures were carried
out strictly in accordance with the Guide for the Care
and Use of Laboratory Animals (National Institutes of
Health, the United States) and the IACUC protocols of
our university (approval no. ACU170501). Mice were
randomly assigned to 5 groups, 9 mice per group and 45
mice in total: negative control group (mice received
drinking water and saline), model group (mice received
DSS in drinking water only), low dose modified PD
group (3.185 g/kg together with DSS), medium dose
modified PD group (6.37 mg/kg together with DSS) and
high dose modified PD group (12.74 mg/kg together
with DSS).
Colitis was induced by providing 2.5% DSS (w/v) to
mice in drinking water for 7 days, and were simultan-
eously given modified PD of different doses since the
first day [10]. Body weight was measured daily and the
animals were sacrificed at day 11 by cervical dislocation,
and their colons were collected. The colon was fixed in
10% formalin for at least 24 h for further histopatho-
logical assessment.
Fig. 6 Modified PD inhibits DSS-induced ulcerative colitis in mice through IL-6/STAT3 pathway
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RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from colon tissues by using
Trizol regent (Invitrogen, US) according to the manufac-
turer’s procedural guidelines, and cDNA was synthesized
by using HiScript RT SuperMix for qPCR kit (Vazyme,
China). Then quantitative real-time PCR was performed
by using iTaq SYBR Green Supermix With ROX kit
(Bio-Rad, US). The specific primers used for detecting
genes are listed in Table 2. All quantitative real-time
PCR experiments were performed with LightCycler 96
System (Roche, Germany). Relative expression of target
genes was normalized to GPADH, analyzed by 2-ΔΔCt
method and given as ratio compared with the control.
The primer sequences are shown as follow.
High-throughput transcriptomic sequencing
RNA samples were sent to the Weifen Biotech (Anhui,
China) for RNA-seq. Briefly, total RNAs were isolated from
triplicates of colon tissues at control group, DSS group and
modified PD group (here we selected the high dose modi-
fied PD group). Three biological repeats were included for
each group. mRNA was extracted from the total RNA after
removing 16 and 23 s rRNAs and then were pooled to-
gether for cDNA synthesis and sequencing. After generat-
ing the clusters, library sequencing was performed on an
Illumina HiSeq2000 platform, to create paired-end reads
with a length of 150 bp. Gene ontology and KEGG pathway
analysis were performed using DAVID.
Western blot
Whole cellular or tissue proteins were extracted with
Pierce RIPA Buffer (Thermo Scientific, US) and protease
inhibitor cocktail (Yeasen, Shanghai, China), then lysates
were transferred to a 1.5-ml microcentrifuge tube and
centrifuged at 12000 rpm for 20 min at 4 °C. The super-
natant was retained and the protein concentration was
normalized to equal level by using BCA Protein Assay
kit (Thermo Fisher, USA). The extracts were separated
by SDS-PAGE and then transferred to 0.45 μm
immobilon-P transfer membrane (Millipore, Bedford,
MA). Membranes were blocked with 5% skim milk for 1
h followed by incubation with a primary antibody at 4 °C
overnight. Then they were washed and treated with an
HRP labeled secondary antibody at 37 °C for 2 h. Immu-
noblots were visualized with the High-sig ECL Western
Blot Substrate (Tannon, Shanghai, China).
Histological analysis
Mice colon tissue was fixed with a sufficient amount of
10% formalin for 24 h. Tissue sections were prepared by
material extraction, dehydration, wax dipping, embedding,
sectioning, HE staining, and coverslipping. The sections
were scanned by digital scanning system and electronic
sections were stored and analyzed on the computer.
The specific scoring method of histological damage is
as follows: the pathological morphological feature in the
visual field is normal intestinal mucosa, 0 point is
scored; the pathological morphological feature is mild
inflammation and edema of the mucosal layer, and the
1/3 crypt in the basal part disappears, 1 point is scored;
It is moderate inflammation of the mucosal layer, 2/3 of
the crypts at the base part disappear, 2 points are scored;
pathological features are moderate inflammation of the
mucosa layer, the crypts completely disappear, but the
epithelial layer is still intact, 3 points are scored; patho-
logical features are mucosa inflammation, which was se-
vere in the stroma, submucosa, and myometrium, and
the crypts and epithelium disappeared, 4 points were
scored [30–32].
Statistical analysis
All data were presented as means ± standard deviation
(SEM). One-way analysis of variance (ANOVA) was used
to evaluate the data between two experimental groups.
For all analyses, p < 0.05 were considered statistically sig-
nificant. They were undertaken using the GraphPad
Prism software (GraphPad Software Inc., Avenida, CA).
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